anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Environmental enteric dysfunction (EED) is an intestinal disorder common among people living in low-resource settings (LRS), which in children has been associated with increased risk of growth stunting, reduced cognitive development, and reduced oral vaccine responsiveness. An effective EED therapeutic would offer an opportunity to improve child growth and development in LRS. One promising intervention, enterade® (an amino acid-based oral rehydration solution \[AA-ORS\]), is a medical food product already sold in the United States. It consists of oral rehydration salts and a proprietary blend of amino acids designed to restore gut function, improve nutrient and electrolyte absorption, and improve barrier integrity. There is evidence that this AA-ORS reduces inflammation and promotes healing of damaged intestinal epithelium in murine models of intestinal damage (irradiated gut), and it may provide benefit to pediatric EED patients. Supplementation of amino acids may lessen or improve intestinal injury related to enteric illnesses commonly experienced in settings of poor hygiene and sanitation infrastructure. The results from this exploratory mixed-methods study could have broad implications for possible future studies among pediatric patients with intestinal injury resulting from EED and future product development and program strategies for EED interventions.

The study was terminated prematurely after study product was found on site that did not meet product specifications. Enrollment and all study product dosing was halted; previously enrolled participants were followed through planned study visits and assessments. An additional 6-week safety follow-up period was added to study procedures. No study-related adverse events were reported during per-protocol activities or from the additional 6-week follow-up.
The invention relates to the technical field of medicines, in particular to application of Triapine in treating African swine fever virus infection. The application of Triapine and salt form, hydrate, solvate and isotope substitute thereof in preparing a medicament for treating African swine fever virus. The invention has the advantages that: (1) triapine has low toxicity to cells and is safe. (2) Triapine has good antiviral effect, and can effectively treat African swine fever virus infection. (3) High selectivity coefficient and safety. (4) Can be used in combination to enhance the treatment effect of African swine fever virus infection.
Currently at Geisinger Medical Center Danville, use of the peanut ball is at the discretion of attending or resident physicians, or obstetric nurses on the Labor and delivery team for the day. Despite the common use of this labor adjuvant tool, a well-designed prospective study is necessary to investigate if the peanut ball provides any benefit during the labor process for the obese gravida. If this simple tool is shown to reduce the rate of cesarean delivery, then hospital protocols could be changed to ensure its use during labor. This has the potential to decrease the rate of cesarean delivery in the most vulnerable patient population. The investigators propose a randomized controlled trial (RCT) to determine if using the peanut ball during labor provides a reduction in the cesarean delivery rate in the obese patient population. The investigators will compare cesarean delivery rates in patients using the peanut ball to patients receiving routine intrapartum management without the use of the peanut ball. Singleton pregnancies complicated by obesity, defined by pre-pregnancy BMI \> 30kg/m2, will be included.

Study participants will be randomized to one of the two study arms. The peanut ball arm (also referred to as study arm 1) will be managed according to the parameters specified for use of the peanut ball. The participants in the Control arm (also referred to as study arm 2) will be managed according to the standard intrapartum management as defined by Geisinger's Labor \& Delivery protocol and per the OB providers. The objective of the study is to determine if use of the peanut ball during labor reduces the cesarean delivery rate in the obese patient population. Secondary outcomes of interest include rate of cervical dilation, rate of operative deliveries, fetal position (occiput anterior vs. occiput posterior) at complete dilation (10 cm), and patient satisfaction.
The present invention relates to crystalline erlotin dihydrochloride and methods for its preparation. Furthermore, the present invention relates to the use of crystalline erlotin dihydrochloride for the preparation of a pharmaceutical composition. The invention further relates to pharmaceutical compositions comprising an effective amount of crystalline erlotin dihydrochloride. The pharmaceutical composition of the invention can be used as a medicament, in particular for the treatment and/or prevention of bacterial infections, for example caused by gram-negative or gram-positive pathogens, in particular caused by multi-drug resistant gram-negative pathogens. Thus, the pharmaceutical composition of the present invention may be used as a medicament for e.g. the treatment of complex intra-abdominal and urinary tract infections.
Application of a compound 1, or a solvate, crystal or salt thereof in the preparation of drugs for preventing and/or treating tumors. Further provided is application of the compound 1, or the solvate, crystal or salt thereof in preparation of a mesoporous material, a drug delivery system, a drug carrier and a manual channel. Experiments have proven that the compound 1 has a high-activity lung cancer resisting effect, may significantly inhibit growth of A549 cells, and the inhibition effect thereof is even better than that of a positive control drug. Thus, the compound has great prospects in the preparation of drugs for preventing and/or treating tumors. In addition, the compound 1 also has good thermal stability and has an obvious layering structure and high porosity. Such a structure enables the compound to have great application potential in the field of preparing the mesoporous material, drug loading materials and manual channel materials.
PURPOSE: To quickly and precisely measure nortripterin by producing an antibody by antigenic conjugate, and using an enzyme conjugate as a reagent. CONSTITUTION: A novel compound is formed of a derivative having a functional group conjugable with a poly(amino acid), which is antigenic or enzyme, in ternary position. The antigenic conjugate is used as an immunogen for producing an antibody to nortripterin. The antibody is used for immunoassay. Enzyme conjugate is used as a reagent in quantitative enzyme assay of nortripterin. This antibody and enzyme reagent are particularly suitable also for use as quantitative immunoassay of nortripterin, and homogeneous enzyme immunoassay is executed according to a know method.
The surgery for the extraction of third molars is one of the procedures in Dentistry that generates a great picture of anxiety in the patients, due to the expectation of pain and discomfort in the postoperative period, but mainly in the trans-operative period. One of the ways to try to minimize this situation is to use sedation, which is a relatively safe procedure performed by trained professionals and with an accurate indication for anxious patients. There are several protocols in the literature, but few comparative studies. Thus, the objective of this study was to evaluate three sedation protocols. For this purpose, 120 patients who required surgical treatment for extraction of third molars, aged between 18 and 30 years, and whose anxiety was moderate to severe according to the Corah Anxiety Scale from the School of Dentistry of São José Dos Campos (UNESP). These patients were randomly divided into three Groups: Group I - oral sedation with diazempam 5 mg; Group II - oral sedation with midazolam 7.5 mg and Group III - inhalation sedation with 40% of nitrous oxide . Prior to sedation, anxiety was quantified through the Corah Anxiety Scale. Vital signs (blood pressure, heart rate and oxygen saturation) were measured before sedation, after sedation, in the trans-operative period and 15 minutes after the end of sedation. The results will be submitted to descriptive statistics and compared using the statistical analysis of variance (ANOVA) and Tukey test with significance level of 5%.
Described is a new class of small molecule inhibitors of amyloid .beta. protein (A.beta.) aggregation, based on apomorphine. These molecules target the nucleation phase of A.beta. self-assembly and interfere effectively with aggregation of A.beta. 1-40 into amyloid fibrils invitro as determined by transmission electron microscopy, Thioflavin T (ThT) fluorescence, and velocity sedimentation. Structure-activity studies using apomorphine analogu es demonstrate that 10, 11-dihydroxy substitutions of the D ring are preferred for the inhibitory effectiveness of these aporphines, and that methylation o f these hydroxyl groups reduces their inhibitory potency. The ability of these small molecules to inhibit A.beta. amyloid fibril formation appears to be linked to their ability to undergo auto-oxidation in solution, implicating a n auto-oxidation product as the active A.beta., inhibitor. Sedimentation velocity and electron microscopy studies demonstrate that apomorphine and analogues facilitate oligomerization of A.beta. into short nonfibrillar soluble assemblies, but inhibit A.beta. fibrilization.
OBJECTIVES: TAM receptors (TYRO3, AXL, and MER) play important roles in inflammatory responses, but their effects in chronic rhinosinusitis with nasal polyps (CRSwNP) remain elucidated. We aim to evaluate the values of TAM receptors in disease severity and postoperative recurrence of CRSwNP.
METHODS: We initially enrolled 160 patients with CRSwNP who were treated with functional endoscopic sinus surgery (FESS) and postoperative recurrence was evaluated during the follow-up period. Circulating TAM receptor levels were detected by enzyme-linked immunosorbent assay (ELISA), and tissue expressions were measured by real-time polymerase chain reaction (RT-PCR) and immunohistochemical (IHC). The relationships between TAM receptor levels and postoperative recurrence were examined.
RESULTS: A total of 150 patients completed the follow-up schedule, 49 patients experienced postoperative recurrence and the remaining 101 patients were non-recurrent. In recurrent CRSwNP patients, serum levels of TAM receptors were increased compared to those in non-recurrent patients and were positively correlated with disease severity scores (P < 0.05). Circulating TYRO3 and MER were identified as potential predictors of postoperative recurrence based on receiver operating characteristics (ROC) and Kaplan-Meier plots (P < 0.05). Furthermore, tissue TAM receptor levels, as determined by both RT-PCR and IHC, were enhanced in the recurrent group than in the non-recurrent group (P < 0.05) and were predictive of postoperative recurrence (P < 0.05). Interestingly, circulating TYRO3 and MER concentrations, as well as tissue TYRO3 expression, were found to be significantly increased in patients who experienced postoperative recurrence (P < 0.05). IHC images from the same patients revealed that TAM expressions were enhanced in the recurrent tissues compared to their baseline tissue levels.
CONCLUSIONS: Our laboratory results demonstrated that TAM receptors were increased in recurrent CRSwNP patients and associated with postoperative recurrence. Moreover, the new laboratory findings suggested that measuring circulating levels of TAM receptors might serve as a promising new approach to assess disease progression and predict the risk of postoperative recurrence.
The invention discloses a Levetiracetam tablet and preparation method thereof. Levetiracetam is a bolus injection medicine with bad compressibility and proportion of supplementary materials which can be added is small. Quality of Levetiracetam is unstable and it is hard to produce Levetiracetam industrially. The invention comprises components of weight percentage content: 70% to 80% of Levetiracetam as active component, 1.5% to 8.0% of plasticizer, 9% to 17% of disintegrant, 3% to 14% of filler, 0.1% to 0.5% of bond and 0.1% to 3% of fluidizer. Addition of plasticizer is added by inner way of wet granulation. Levetiracetam as active component has bad mechanic compressibility. The invention adds plasticizer to solve tablet compression difficulty in industrial embodiment thoroughly, which realizes the purpose of being suitable for coating with stable quality and easy industrial application.
Provided are methods of producing cobalt-based nanoparticles (Co x B y  NPs) of a pre-selected diameter. The methods include reducing Co 2+  ions with a sodium borohydride (NaBH 4 ) solution having a selected ratio of tetrahydroxyborate (B(OH) 4   − ) to tetrahydroborate (BH 4   − ) based on the pre-selected diameter, where the ratio of B(OH) 4   −  to BH 4   −  is positively correlated with the pre-selected diameter. Also provided are methods of using the Co x B y  NPs to produce hollow metal nanospheres (HMNs). Methods of producing Co x B y  NP core/metal shell structures are also provided, such methods including combining in an anaerobic galvanic exchange reaction a deaerated solution including Co x B y  NP scaffolds and a deaerated solution including a metal. Also provided are methods of producing HMNs from the Co x B y  NP core/metal shell structures. Compositions and kits that find use in practicing the methods of the present disclosure and using HMNs produced in accordance with the methods of the present disclosure, are also provided.
Letrozole is an aromatase inhibitor used in the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women.It has more recently been approved for use in many countries as adjuvant therapy for early breast cancer; and is often used in an adjuvant regimen following 2-3 years of tamoxifen treatment or as an extended adjuvant therapy after up to 5 years of tamoxifen. Letrozole inhibits the conversion of androgens to estrogens in vitro and in vivo. Plasma levels of estradiol and related estrogen compounds in postmenopausal patients receiving letrozole are suppressed up to 95% from baseline and are often undetectable.The estrogen deprivation in women receiving letrozole may cause increased bone resorption and bone loss.Studies comparing tamoxifen and aromatase inhibitors, in adjuvant therapy have shown an increase fracture rate, and decreased bone mineral density in patients receiving aromatase inhibitors. Zoledronic acid is an intravenously administered bisphosphonate that inhibits osteoclastic bone resorption. Intravenous bisphosphonates are effective in reducing the rate of skeletal complications, including fractures, in patients with metastatic breast cancer and other tumors when given every few weeks. Small clinical trials have given some evidence that osteoporosis can be effectively treated by one or two doses of intravenous zoledronic acid per year. This study will determine the effect of giving zoledronic acid every 6 months on the bone mineral density of patients receiving letrozole as adjuvant therapy for early breast cancer after having received adjuvant tamoxifen for at least 2.5 years. Patients will be randomized to receive zoledronic acid either at the start of letrozole therapy or when bone mineral density T score drops below - 2 standard deviation or at the occurrence of a non-trauma related fracture.
The invention discloses a traditional Chinese medicine for treating mania caused by traumatic brain injury and relates to a traditional Chinese medicine. The traditional Chinese medicine for treating mania caused by traumatic brain injury is used for solving the problem that a patient with traumatic brain injury has mania. After being applied at the early stage, the traditional Chinese medicine is capable of promoting the patient to recover more quickly, so that the harms of the mania to the patient, the family and the society are reduced or eliminated. The traditional Chinese medicine for treating mania caused by traumatic brain injury is prepared from the following components in parts by weight: 30 parts of dried rehmannia roots, 30 parts of radix ophiopogonis, 30 parts of radix scrophulariae, 25 parts of poria cocos, 25 parts of rhizoma coptidis, 25 parts of lophatherum gracile, 20 parts of tabasheer, 20 parts of cooked jujube kernel, 20 parts of nacre mother of pearl (decocted earlier), 18 parts of lilies, 18 parts of tribulus terrestris, 18 parts of rhizoma anemarrhenae, 18 parts of platycladi seeds, 15 parts of radix cureumae, 15 parts of cortex albiziae, 15 parts of polygala tenuifolia and 10 parts of honey-fried licorice root. The traditional Chinese medicine for treating mania caused by traumatic brain injury is free of use of toxic traditional Chinese medicine components, free of toxic and side effect and low in cost, and can be used for treating mania caused by various traumatic brain injuries. Moreover, the course of treatment is about 20-30 days, the curative effect is good, the effective rate is 100%, and the cure rate is 85% and more than 85%.
BACKGROUND: Autism and autistic traits onset in childhood but persist into adulthood. Little is known about how genetic and environmental factors influence autism and autistic traits into adulthood. We aimed to determine age effects on the heritability of clinically diagnosed autism and the etiological stability of autistic traits from childhood to adulthood using twin methods.
METHODS: From 23,849 twin pairs in the Swedish Twin Register born between 1959 and 2010, we identified 485 individuals (1.01%, 31.5% female) with a clinical autism diagnosis. We estimated and compared the relative contribution of genetic, shared, and nonshared environmental influences to autism in childhood and adulthood. We further used multivariate twin analysis with four measurement points among 1,348 twin pairs in the longitudinal Twin Study of Child and Adolescent Development to assess the phenotypic and etiological stability of autistic traits - measured with three scales from the Child Behavior Checklist - from childhood to adulthood.
RESULTS: Autism heritability was comparable from childhood, (96% [95% CI, 76-99%]) to adulthood (87% [67-96%]). Autistic traits were moderately stable (phenotypic correlation = 0.35-0.61) from childhood to adulthood, and their heritability varied between 52 and 71%. We observed stable as well as newly emerging genetic influences on autistic traits from ages 8-9 to 19-20, and unique nonshared environmental influences at each age.
CONCLUSIONS: Genetic factors are important for autism and autistic traits in adulthood and separate genetic studies in adults are warranted.
Current research is mainly focused on evaluating the effect of robotic rehabilitation on locomotion in ALS. In order to understand this approach, it is important to validate its safety and to determine patient's experience with this new rehabilitation concept in ALS. In this study, we aim to evaluate the safety, the participant experience and effectiveness of the training program with the Atalante exoskeleton as a gait training tool for ALS patients, compared with usual care, on walking ability, functional capacity and other symptoms associated with motor disability. The Atalante exoskeleton is the only self-balancing exoskeleton that enables assisted walking without walking aid, reproducing a natural walking pattern and multidirectional movement. EXALS is an interventional, monocentric, prospective, open trial. With a limited number of studies on gait rehabilitation exoskeletons in ALS, this study represents a significant scientific contribution, being the first to explore the benefits of a self-balancing exoskeleton with a rigorous design. In addition to robust outcome measures, this study places importance on participants' perception, motivation, and involvement in decision-making, adding depth and strength to the research.
This pragmatic adaptive clinical trial will test the effects of a Stigma-Motivational-Decision intervention designed to increase HIV treatment engagement, retention, and antiretroviral (Art) medication adherence for substance using adolescents and young adults (AYA) living with HIV who are not in clinical care. The intervention uses a uniquely unified counseling approach at multiple points along the HIV continuum of care. In a first step, the study will use multiple modes of outreach including social media, passive media, clinic records, and chain referrals to seek and identify HIV positive AYA who are HIV untreated, under-dosed, or unsuppressed (HIV-U3). Identified AYA will be enrolled in a run-in to the trial to objectively confirm the following criteria for trial entry. In Step 2, Individuals who meet entry criteria -specifically - substance using HIV-U3 AYA - will be enrolled in a mobile health (mHealth) intervention to address substance use, HIV stigmas, medical care-related concerns, structural barriers, and other challenges to engaging youth in HIV care. Counseling will be provided weekly by cellphone until the time participants are receiving ART, adequately dosed on ART, and HIV suppressed within a maximum of 12 sessions (up to 3-months). The study will therefore determine the number of theory-based mHealth intervention sessions needed (minimally effective dose) for optimal treatment outcomes and the associated costs. Once engaged and optimally treated, Step 3 will conduct a randomized trial to test the comparative effects and cost effectiveness of two interventions to sustain long-term retention in care and medication adherence: (a) interactive text messaging with opportunities for ongoing supportive problem solving vs. (b) passive text message reminders. HIV positive AYA are likely to drop out of care because of known challenges such as substance use, social barriers such as stigma, and concerns regarding treatment. The 3-step study will use a single theory-based approach to determine the number of phone-delivered Stigma-Motivational-Decision counseling intervention sessions necessary to achieve engagement or re-engagement in HIV care, and will test the effects of a low-cost approach to sustaining long-term retention in care and medication adherence. The study will determine the minimally effective amount of counseling needed to engage substance using HIV positive AYA in care. The study will also test the effects of the counseling and text messaging interventions on maintaining HIV care retention, medication adherence, and HIV viral suppression over 18-months. The study will perform economic evaluations to determine the cost-effectiveness of the engagement-retention-adherence intervention and the effects of low-burden retention/adherence interventions to maintain retention in care and avoid relapse to non-adherence for AYA living with HIV.
ToM training was composed of six lessons two times a week. Through several types of stimuli, the trainer worked together with the participant to comprehend and hypothesize interpretations of the emotions and social interactions, providing discussion occasions to enhance the attribution of mental states and emotions. Every lesson had a duration of 45/60 minutes in order to avoid excessive fatigue in the participant.